title: [Prevention and release of epidural-morphine-induced urinary retention with phenoxybenzamine and neostigmine].
abstract: OBJECTIVE
  To study the effects of preoperative phenoxybenzamine (o.p) on preventing epidural-morphine-induced urinary retention and effects of neostigmine on releasing it.
  
  
  METHODS
  80 patients who received epidural morphine to release postoperative pain were divided into 4 groups randomly and received preoperative phenoxybenzamine (group P, n = 20), neostigmine (i. m) when urinary retention happened (group N, n = 20), both drugs (group U, n = 20), and without drugs (Control, n = 20), respectively. The incidences of urinary retention and release were observed.
  
  
  RESULTS
  No significant decrease (P > 0.05) happened after operation in the incidence of epidural-morphine-induced urinary retention both in the group P and in the group N. Neostigmine(i. m) could significantly release (P < 0.001) the epidural-morphine-induced urinary retention when phenoxybenzamine was administrated preoperatively.
  
  
  CONCLUSIONS
  Preoperative phenoxybenzamine can not prevent epidural-morphine-induced urinary retention. Neostigmine can release the urinary retention only when preoperative phenoxybenzamine is used.
authors.affiliation: Department of Anesthesiology, the 4th Hospital of Zhenjiang, Zhenjiang 212001, China. tpopo@yeah.net
authors.forename: J
authors.initials: J
authors.lastname: Tang
authors.forename: Q
authors.initials: Q
authors.lastname: Xu
authors.forename: T
authors.initials: T
authors.lastname: Ye
mesh_terms: D000293:Adolescent; D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D015360:Analgesia, Epidural; D000701:Analgesics, Opioid / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009020:Morphine / Q000009:adverse effects* / Q000627:therapeutic use; D009388:Neostigmine / Q000627:therapeutic use*; D010149:Postoperative Pain / Q000188:drug therapy; D010277:Parasympathomimetics / Q000627:therapeutic use*; D010643:Phenoxybenzamine / Q000627:therapeutic use*; D016896:Treatment Outcome; D016055:Urinary Retention / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000317:Adrenergic alpha-Antagonists; D000701:Analgesics, Opioid; D010277:Parasympathomimetics; D010643:Phenoxybenzamine; D009388:Neostigmine; D009020:Morphine